Corbus Pharmaceuticals (NASDAQ: CRBP) lands FDA clearance for TEMPO-1 as CRB-701 enters Phase 3

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) said on 28 July that the U.S. Food and Drug Administration has cleared its registrational study, TEMPO-1, of the Nectin-4 targeted antibody drug conjugate CRB-701 in second-line oropharyngeal squamous cell carcinoma. The clearance moves the Norwood, Massachusetts, clinical-stage company out of Phase 1/2 exploration and into a randomised 250-patient study that management expects to begin enrolling in September 2026. It is the single most important regulatory de-risking event Corbus has secured for CRB-701 since it disclosed FDA alignment on the trial design earlier this year. The central tension is that the same asset produced a confirmed response rate impressive enough to justify an accelerated approval strategy, and an ocular safety profile serious enough to trigger a roughly 30 percent share-price decline on the day the Phase 1/2 data landed at the American Society of Clinical Oncology annual meeting. TEMPO-1 will now have to reproduce the efficacy while making the tolerability story credible to prescribers and to regulators reviewing an accelerated approval package.

How does FDA clearance of TEMPO-1 change the regulatory risk profile for CRB-701 in second-line OPSCC?

The FDA’s decision to allow TEMPO-1 to proceed converts a design-alignment conversation into a live registrational trial. Corbus had already disclosed that it had reached broad alignment with the agency on the study, with objective response rate as the primary endpoint intended to support potential accelerated approval and overall survival as a secondary endpoint intended to support conversion to full approval. What has changed is that the FDA has cleared the actual protocol for enrolment, which removes the residual risk that a regulatory objection could still reshape the trial before the first patient dosed. That is a meaningful step for a company whose entire near-term investment case now rests on CRB-701 delivering data at least broadly consistent with the Phase 1/2 dose-optimised cohort.

TEMPO-1 is a 250-patient randomised controlled study comparing CRB-701 against investigator’s choice of capecitabine, cetuximab or docetaxel. That control arm is worth pausing on. It is the standard of care that Corbus itself, and independent clinical opinion, describe as providing limited efficacy in second-line OPSCC. A control designed around three legacy agents rather than an immunotherapy backbone gives CRB-701 a lower bar to clear on ORR than a comparator built around pembrolizumab, and it is one of the reasons the regulatory pathway is credible in a study of only 250 patients rather than the multi-hundred-patient Phase 3 designs typical of head-and-neck oncology.

The remaining regulatory risk is therefore not whether the FDA supports the study concept. It is whether the confirmed ORR translates from a dose-selected Phase 1/2 cohort of a few dozen patients to a randomised, blinded, multi-site enrolment. Registrational trials have historically compressed early biotech response signals, and Corbus does not have a second independent study of comparable size to fall back on if TEMPO-1 underperforms.

Why does 2L oropharyngeal cancer look like a distinct commercial opportunity rather than a subset of head and neck disease?

Corbus is treating OPSCC as a standalone commercial opportunity rather than a slice of the broader head-and-neck franchise, and the epidemiology supports that framing. Approximately 14,000 patients in the United States are estimated to be eligible for second-line treatment each year, with roughly 7,000 dying from the disease annually. Management says the OPSCC subset represents about half of head-and-neck cancer patients in the second-line setting, driven overwhelmingly by human papillomavirus infection. The patient profile that has emerged, men in their fifties and sixties with little or no history of smoking or heavy alcohol use, matters commercially because it defines a distinct clinical population whose treatment decisions are typically made in specialist centres with strong ties to clinical trial infrastructure. That should ease enrolment velocity for TEMPO-1.

The strategic logic of running a dedicated second-line OPSCC trial, rather than a broader HNSCC design, is that it isolates the tumour type where Corbus’s Phase 1/2 data set has been strongest and where Nectin-4 expression is well characterised. It also allows a smaller, faster trial with an ORR-primary design that supports accelerated approval. In parallel, Corbus retains FDA alignment on a separate randomised trial in 2L cervical cancer, another HPV-driven Nectin-4 expressing tumour, which extends the potential label footprint if the platform delivers.

What did the 42.9 percent ORR at 3.6 mg/kg actually tell investors about CRB-701 versus current standard of care?

The efficacy signal that made the FDA willing to authorise a 250-patient registrational study is real. In an analysis of patients with second-line or later OPSCC treated at the 3.6 mg/kg dose, CRB-701 achieved a confirmed objective response rate of 42.9 percent, with a median duration of response of 6.3 months and a median progression-free survival of 5.6 months, both still ongoing at the time of the ASCO 2026 presentation. Against a control arm made up of capecitabine, cetuximab and docetaxel monotherapy, whose response rates in this setting are typically in the low double digits, that gap is the commercial argument for the drug.

Whether that gap holds in a randomised trial is a separate question. The confirmed ORR came from a dose-selected subgroup within a broader Phase 1/2 study of 317 advanced solid tumour patients. Randomisation, longer follow-up and centralised response adjudication typically compress early biotech ORR readings, and the accelerated approval package will need the endpoint to be robust to that pressure. If the TEMPO-1 ORR lands even in the mid-thirties, that would still likely support accelerated approval given the control-arm benchmark, but a decline into the twenties would materially weaken the case.

How should the ocular adverse event profile be read heading into a registrational Phase 3 study?

The tolerability signal is the more contested part of the CRB-701 profile, and it is what investors reacted to in May. In the 317-patient Phase 1/2 safety population, ocular adverse events were reported in 66.2 percent of patients, with 12.6 percent at Grade 3 and one Grade 4 event. Ocular-adverse-event-related discontinuations were 1.9 percent, and overall discontinuations related to CRB-701 were 2.8 percent. Ocular events are a known liability across the Nectin-4 ADC class, given the receptor’s expression in ocular tissue, and the payload choice, monomethyl auristatin E, adds a secondary risk driver.

The market’s reading of that safety profile was severe. Shares fell roughly 30 percent on the day the updated Phase 1/2 data were reported at ASCO. That reaction has anchored the current valuation, and it is important context for how TEMPO-1 will be interpreted. If the Phase 3 confirms a comparable ocular incidence but with low permanent discontinuation and manageable dose modification, the drug can still support an accelerated approval label. If ocular events drive higher discontinuations in a randomised setting, or produce visual outcomes that regulators and prescribers view as unacceptable in a palliative second-line population, the label becomes narrower and the commercial case tightens.

Where does CRB-701 fit inside the Nectin-4 franchise map dominated by Padcev?

Nectin-4 is not a novel target. It has been clinically validated by enfortumab vedotin, marketed as Padcev by Pfizer and Astellas, which has become one of the highest-value ADCs on the market for urothelial cancer. Corbus is not competing with that franchise directly; it is arguing that CRB-701’s engineering profile, a site-specific cleavable linker and a homogenous drug-to-antibody ratio of 2 with MMAE as payload, produces a differentiated tolerability and dosing profile in tumours where Padcev has not been established. The FDA has already granted CRB-701 two Fast Track designations, one in HNSCC and one in cervical cancer, which reflects that positioning.

The strategic point for investors is that Corbus is attempting to build a Nectin-4 franchise in HPV-driven solid tumours where Padcev has essentially no presence, rather than trying to displace the incumbent in urothelial disease. That is a defensible commercial white space if the efficacy and safety trade-off holds up. The hiring of Leonardo Viana Nicacio, M.D., as Chief Medical Officer in July, with prior experience advancing tisotumab vedotin, another ADC in HPV-driven disease, sends the same signal about where the company sees the platform’s commercial identity.

Does the $138 million cash position leave Corbus Pharmaceuticals room to run TEMPO-1 without another raise?

Corbus ended the first quarter of 2026 with $138.2 million in cash, cash equivalents and investments, and management says the balance is expected to fund operations into 2028. That runway was extended by a $75 million public offering completed in the fourth quarter of 2025, and the company has additional flexibility through a $300 million shelf registration and remaining capacity under an at-the-market equity programme.

The financial arithmetic is tighter than the runway statement suggests. Corbus reported a first-quarter 2026 net loss of $23 million, with research and development spending of $19.8 million, and full-year 2025 R&D of $70.1 million. Ramping enrolment across TEMPO-1, the parallel cervical cancer study and the CANYON-1 obesity trial for CRB-913 will likely lift R&D spending as the year progresses. A cash balance of $138 million against a quarterly burn approaching $25 million implies the 2028 runway assumption depends on either the shelf being tapped opportunistically or spending being managed more tightly than the current trajectory suggests. Investors should treat future dilution as a possibility that management retains, not as a risk that has been eliminated.

What are the next measurable proof points investors should track after FDA clearance of TEMPO-1?

The immediate catalyst is the September 2026 enrolment start, followed by any operational updates on site activation and enrolment velocity. Second-quarter 2026 financial results, currently indicated for early August, will provide the first look at how R&D spending is scaling into the trial. Topline data from the 240-patient CANYON-1 Phase 1b study of CRB-913 in obesity, expected in late summer 2026, is a separate readout that could reshape the non-oncology part of the story. And a combination readout for CRB-701 with pembrolizumab, expected in early first-quarter 2027, will influence whether the platform can extend into first-line combinations or remain confined to monotherapy second-line use.

The valuation reflects scepticism. A market capitalisation in the mid-$160 million range for a company entering a registrational Phase 3 in a defined 14,000-patient annual second-line market, with FDA Fast Track designations and cash into 2028, implies that investors are not yet giving management the benefit of the doubt on either the ocular safety story or the reproducibility of the ASCO ORR. TEMPO-1 clearance is a step toward changing that read. It is not, by itself, an answer.

Key takeaways for investors tracking Corbus Pharmaceuticals and the CRB-701 registrational path

• FDA has cleared TEMPO-1, the registrational Phase 3 of CRB-701 in second-line OPSCC, with enrolment expected to begin in September 2026.
• The 250-patient randomised study will compare CRB-701 against investigator’s choice of capecitabine, cetuximab or docetaxel, with ORR as the primary endpoint for potential accelerated approval and OS for potential full approval.
• The design targets an annual U.S. eligible population of roughly 14,000 second-line OPSCC patients, with about 7,000 estimated deaths per year in the United States.
• CRB-701 delivered a 42.9 percent confirmed ORR at the 3.6 mg/kg dose in the Phase 1/2 study, with median duration of response of 6.3 months and median PFS of 5.6 months, both ongoing.
• The Phase 1/2 safety population showed ocular adverse events in 66.2 percent of patients, with 12.6 percent Grade 3 and one Grade 4 event; ocular-related discontinuations were 1.9 percent.
• Shares fell roughly 30 percent on the day the updated Phase 1/2 data were released, indicating that the ocular signal, not the ORR, is currently anchoring investor scepticism.
• Corbus holds two FDA Fast Track designations for CRB-701, in HNSCC and cervical cancer, and retains alignment on a separate randomised trial in 2L cervical cancer.
• The company ended Q1 2026 with $138.2 million in cash, guided runway into 2028, and retains a $300 million shelf plus ATM capacity, which preserves optionality but leaves future dilution possible.
• The next measurable proof points are enrolment start in September, Q2 2026 results in early August, CANYON-1 topline data in late summer, and the CRB-701 plus pembrolizumab readout in early Q1 2027.
• A market capitalisation near $166 million implies limited market confidence in near-term execution; a successful TEMPO-1 readout would be the primary catalyst for a sustained re-rating.